Table 1 Baseline patient demographics and clinical characteristics
Parametera | Overall study cohort (N = 1096) |
|---|---|
Sex, n (%) | |
Male | 721 (65.8) |
Female | 375 (34.2) |
Age, years | 60.6 ± 14.8 |
Country, n (%) | |
Spain | 596 (54.4) |
France | 174 (15.9) |
Portugal | 147 (13.4) |
Italy | 106 (9.7) |
Russia | 73 (6.7) |
Body mass index, kg/m2 [n = 804] | 27.8 ± 6.0 |
Dialysis vintage, months | 61.0 ± 70.0 |
≥ 1 year on dialysis, n (%) | 857 (78.2) |
< 1 year on dialysis, n (%) | 239 (21.8) |
Dialysis modalityb | |
Hemodiafiltration, n (%) | 688 (62.8) |
Hemodialysis, n (%) | 400 (36.5) |
Unknown | 8 (0.7) |
Prior PB use, n (%) | |
Pretreated | 855 (78.0) |
Naïve | 241 (22.0) |
Regimen received by PB-pretreated patients, n (%) | n = 855 |
Calcium-based | 259 (30.3) |
Sevelamer | 224 (26.2) |
Sevelamer + calcium-based | 195 (22.8) |
Lanthanum | 60 (7.0) |
Lanthanum + calcium-based | 47 (5.5) |
Sevelamer + lanthanum | 42 (4.9) |
Sevelamer + lanthanum + calcium-based | 28 (3.3) |
Charlson Comorbidity Index at end of baseline period | 3.8 ± 1.9 |
Age-adjusted Charlson Comorbidity Index at end of baseline period | 5.5 ± 2.6 |
Comorbidities, n (%)c | |
Hypertension | 717 (65.4) |
Diabetes | 319 (29.1) |
Congestive heart failure | 274 (25.0) |
Peripheral vascular disease | 256 (23.4) |
Cerebrovascular disease | 143 (13.1) |
Chronic pulmonary disease | 122 (11.1) |
Malignant tumor | 116 (10.6) |
Myocardial infarction | 102 (9.3) |
Liver disease | 82 (7.5) |
Peptic ulcer disease | 57 (5.2) |